Eli Lilly and Company (NYSE:LLY) Shares Bought by Bank of Hawaii

Bank of Hawaii raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,612 shares of the company's stock after acquiring an additional 374 shares during the period. Bank of Hawaii's holdings in Eli Lilly and Company were worth $7,420,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. Phoenix Financial Ltd. grew its holdings in shares of Eli Lilly and Company by 12.4% in the fourth quarter. Phoenix Financial Ltd. now owns 19,037 shares of the company's stock valued at $14,697,000 after purchasing an additional 2,096 shares in the last quarter. Mountain Capital Investment Advisors Inc. lifted its position in Eli Lilly and Company by 46.1% during the fourth quarter. Mountain Capital Investment Advisors Inc. now owns 371 shares of the company's stock valued at $269,000 after purchasing an additional 117 shares during the last quarter. Evexia Wealth LLC grew its stake in shares of Eli Lilly and Company by 1.7% in the 4th quarter. Evexia Wealth LLC now owns 12,341 shares of the company's stock worth $9,527,000 after buying an additional 206 shares in the last quarter. CenterBook Partners LP increased its holdings in shares of Eli Lilly and Company by 826.4% in the 4th quarter. CenterBook Partners LP now owns 19,306 shares of the company's stock worth $14,904,000 after buying an additional 17,222 shares during the last quarter. Finally, Kraft Davis & Associates LLC increased its holdings in shares of Eli Lilly and Company by 23.2% in the 4th quarter. Kraft Davis & Associates LLC now owns 361 shares of the company's stock worth $279,000 after buying an additional 68 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Up 2.1 %

Shares of LLY stock traded up $15.14 during mid-day trading on Monday, hitting $747.55. The stock had a trading volume of 1,488,839 shares, compared to its average volume of 3,379,060. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm's 50-day moving average is $837.05 and its two-hundred day moving average is $822.87. The firm has a market capitalization of $708.80 billion, a P/E ratio of 63.84, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on LLY. Morgan Stanley dropped their price target on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a report on Friday, January 17th. Citigroup decreased their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Guggenheim lowered their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research report on Monday. Finally, Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Two research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,012.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.